Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082459 · ClinicalTrials.gov registry record · Phase 2
Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Agenus.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00082459 is a Phase 2 study that was terminated before completion, run by Agenus. The registered enrollment target is 40 participants.
The verdict
NCT00082459, a Phase 2 study, was terminated before completion, sponsored by Agenus.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient's tumor.
Interventions
- BIOLOGICAL autologous human tumor-derived HSPPC-96
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-07 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082459
The ClinicalTrials.gov registry entry for NCT00082459 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which autologous human tumor-derived HSPPC-96 is the first listed.
NCT00082459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082459 about?
NCT00082459 is a clinical study titled "Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma". The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient's tumor.
What is the current status of trial NCT00082459?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2002-07. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00082459?
The interventions under investigation include: autologous human tumor-derived HSPPC-96 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00082459?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.